Evidence map›Paper›PMID 32290029›Full record

ReviewMolecules (Basel, Switzerland)2020

New Frontiers for the Use of IP6 and Inositol Combination in Treating Diabetes Mellitus: A Review.

Felix O Omoruyi, Dewayne Stennett, Shadae Foster, Lowell Dilworth

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Physiological and Metabolic Responses of Wheat (ACS agricultural science & technology · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Grading of endometrial cancer usingScientific reports · 2021
    Article
  18. Bioactivity of Inositol Phosphates.Molecules (Basel, Switzerland) · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Felix O OmoruyiDepartment of Life Sciences, Texas A&M University, Corpus Christi, TX 78412, USA.ORCID 0000-0001-6926-8097
Dewayne StennettDepartment of Basic Medical Sciences, the University of the West Indies, Mona Campus, Kingston, Jamaica.
Shadae FosterDepartment of Basic Medical Sciences, the University of the West Indies, Mona Campus, Kingston, Jamaica.
Lowell DilworthDepartment of Pathology, the University of the West Indies, Mona Campus, Kingston, Jamaica.
University of the West Indies System · JMTexas A&M University – Corpus Christi · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inositol, or myo-inositol, and associated analog molecules, including myo-inositol hexakisphosphate, are known to possess beneficial biomedical properties and are now being widely studied. The impact of these compounds in improving diabetic indices is significant, especially in light of the high cost of treating diabetes mellitus and associated disorders globally. It is theorized that, within ten years, the global population of people with the disease will reach 578 million individuals, with the cost of care projected to be approximately 2.5 trillion dollars. Natural alternatives to pharmaceuticals are being sought, and this has led to studies involving inositol, and myo-inositol-hexakisphosphate, also referred to as IP6. It has been reported that IP6 can improve diabetic indices and regulate the activities of some metabolic enzymes involved in lipid and carbohydrate metabolism. Current research activities have been focusing on the mechanisms of action of inositol and IP6 in the amelioration of the indices of diabetes mellitus. We demonstrated that an IP6 and inositol combination supplement may regulate insulin secretion, modulate serum leptin concentrations, food intake, and associated weight gain, which may be beneficial in both prediabetic and diabetic states. The supplement attenuates vascular damage by reducing red cell distribution width. Serum HDL is increased while serum triglycerides tend to decrease with consumption of the combination supplement, perhaps due to the modulation of lipogenesis involving reduced serum lipase activity. We also noted increased fecal lipid output following combination supplement consumption. Importantly, liver function was found to be preserved. Concurrently, serum reactive oxygen species production was reduced, indicating that inositol and IP6 supplement consumption may reduce free radical damage to tissues and organs as well as serum lipids and blood glucose by preserving liver function. This review provides an overview of the findings associated with inositol and IP6 supplementation in the effective treatment of diabetes with a view to proposing the potential mechanisms of action.

Indexed as

Dietary SupplementsAnimalsBiomarkersBlood Cell CountCarbohydrate MetabolismDiabetes MellitusDrug Therapy, CombinationHumansHypoglycemic AgentsInositolIntestinesLeptinLipid MetabolismMetabolic Networks and PathwaysPhytic AcidTreatment OutcomeBiomarkersHypoglycemic AgentsInositolLeptinPhytic Aciddiabetes mellitusfree radicalinositolIp6lipidmyo-inositol

Identifiers

PMID32290029
PMCPMC7212753
OpenAlexW3015648033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.